Ac-crown-TATE

Ac-crown-TATE ([²²⁵Ac]Ac-crown-TATE; 30 kBq; tail vein injection; 1-120 h) rapidly accumulates in tumors in SSTR2-positive AR42J tumor-bearing NRG mice. The tumor uptake increases from 7.8% IA/g at 1 h to 11.1% IA/g at 4 h, remains > 5% IA/g even at 120 h, and the tumor biological half-life is 148.3 h^[1].
Ac-crown-TATE ([²²⁵Ac]Ac-crown-TATE; 30 or 55 kBq; observation up to 60 days) slows the growth of AR42J tumors and prolongs median survival to 21 and 26 days, respectively, compared with 4 and 5 days in saline and non-radioactive crown-TATE controls^[1].
Ac-crown-TATE ([²²⁶Ac]Ac-crown-TATE; 58.6 kBq; tail vein injection; 1-48 h) exhibits high tumor uptake in AR42J tumor-bearing NRG mice, reaching 33.1% IA/g at 5 h and remaining at 19.7% IA/g at 48 h, with a tumor absorbed dose coefficient of 222.3 mGy/kBq^[2].
Ac-crown-TATE ([²²⁶Ac]Ac-crown-TATE; 125, 250 or 375 kBq; observation for up to 60 days) slows tumor growth in AR42J tumor-bearing NRG mice, and extends the median survival time from 7 days (seen in the two control groups) to 16, 24 and 27 days, respectively. No significant body weight loss or toxicity is observed in any dose group^[2].